导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.51% | 4146/4773 |
| 近一周 | - | 406/5458 |
| 近一月 | -0.18% | 868/5421 |
| 近一季 | -7.27% | 3488/5205 |
| 近半年 | -18.16% | 4296/4920 |
| 近一年 | -4.18% | 3136/4361 |
| 近两年 | 39.90% | 1950/2954 |
| 近三年 | 10.32% | 1743/2253 |
| 成立以来 | 108.18% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.67% 3666/4961 |
-1.90% 3376/5312 |
- - |
- - |
| 2025 | 29.31% 1410/4813 |
-1.85% 2795/3635 |
11.11% 218/4076 |
7.14% 3474/4524 |
10.67% 183/4813 |
| 2024 | 7.88% 1610/3463 |
-5.88% 1963/2808 |
-2.46% 1192/3014 |
12.47% 2337/3129 |
4.48% 703/3463 |
| 2023 | -10.78% 1335/2656 |
0.84% 1687/2280 |
2.88% 120/2385 |
-10.30% 1981/2515 |
-4.13% 880/2655 |
| 2022 | -25.18% 1294/2207 |
-21.67% 1646/1919 |
3.76% 1095/2016 |
-7.25% 117/2113 |
-0.74% 1644/2208 |
| 2021 | 13.99% 346/1822 |
-17.43% 1200/1255 |
9.97% 505/1330 |
7.22% 192/1466 |
17.08% 46/1822 |
| 2020 | 63.20% 111/1250 |
-1.43% 216/1022 |
10.70% 754/1060 |
27.32% 18/1152 |
- - |
| 2019 | 20.07% 671/1092 |
30.07% 254/748 |
-9.05% 626/797 |
3.02% 271/844 |
-1.48% 895/912 |
| 2018 | -26.90% 407/834 |
- - |
- - |
- - |
-13.63% 545/691 |
| 2017 | -17.74% 572/714 |
- - |
- - |
- - |
- - |
| 2016 | -23.76% 466/605 |
- - |
- - |
- - |
- - |
| 2015 | 38.08% 50/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 富国中证军工指数(LOF)A VS. 长安沪深300非周期A(740101) |